STRO - Sutro Biopharma Inc Stock Price, Fair Value and News

3.52USD-0.20 (-5.38%)Delayed as of 24 Apr 2024, 01:07 pm ET

Market Summary

USD3.52-0.20

Delayedas of 24 Apr 2024, 01:07 pm

-5.38%

STRO Alerts

Point72 Asset Management, L.P. reported owning 7.7% of STRO [2024-04-05]

STRO Stock Price

View Fullscreen

STRO RSI Chart

STRO Valuation

Market Cap

232.3M

Price/Earnings (Trailing)

-2.18

Price/Sales (Trailing)

1.51

EV/EBITDA

-2.02

Price/Free Cashflow

-2.08

STRO Price/Sales (Trailing)

STRO Profitability

EBT Margin

-57.63%

Return on Equity

-71.36%

Return on Assets

-22.69%

Free Cashflow Yield

-48.05%

STRO Fundamentals

STRO Revenue

Revenue (TTM)

153.7M

Rev. Growth (Yr)

1.2K%

Rev. Growth (Qtr)

571.95%

STRO Earnings

Earnings (TTM)

-106.8M

Earnings Growth (Yr)

189.8%

Earnings Growth (Qtr)

163.03%

Breaking Down STRO Revenue

52 Week Range

3.116.11

(Low)(High)

Last 7 days

-5.6%

Last 30 days

8.8%

Last 90 days

-18.9%

Trailing 12 Months

-19.1%

How does STRO drawdown profile look like?

STRO Financial Health

Current Ratio

4.5

STRO Investor Care

Shares Dilution (1Y)

3.79%

Diluted EPS (TTM)

-1.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	74.5M	56.9M	48.6M	153.7M
2022	53.1M	53.2M	69.8M	67.8M
2021	50.2M	68.8M	59.5M	61.9M
2020	41.3M	40.2M	45.7M	42.7M
2019	41.3M	46.1M	50.5M	42.7M
2018	41.0M	31.3M	21.7M	36.7M
2017	57.7M	55.7M	53.7M	51.7M
2016	0	0	0	59.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sutro Biopharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	srinivasan venkatesh	sold (taxes)	-34,119	4.5	-7,582	chief tech op officer
Apr 11, 2024	srinivasan venkatesh	acquired	-	-	21,250	chief tech op officer
Mar 05, 2024	albini edward c	sold (taxes)	-14,074	4.54	-3,100	cfo and secretary
Mar 05, 2024	albini edward c	acquired	-	-	8,750	cfo and secretary
Mar 05, 2024	fitzpatrick linda a	acquired	-	-	8,750	chief people & comm. officer
Mar 05, 2024	fitzpatrick linda a	sold (taxes)	-14,110	4.54	-3,108	chief people & comm. officer
Mar 05, 2024	newell william j	acquired	-	-	18,750	ceo
Mar 05, 2024	newell william j	sold (taxes)	-30,372	4.54	-6,690	ceo
Mar 04, 2024	chung jane	acquired	-	-	7,875	president and coo
Mar 04, 2024	chung jane	sold (taxes)	-10,581	4.79	-2,209	president and coo

Which funds bought or sold STRO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	23,271	121,750	-%
Apr 18, 2024	Diversified Trust Co	added	16.46	25,625	73,625	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	98.17	247,644	401,466	0.01%
Apr 12, 2024	AdvisorNet Financial, Inc	new	-	2,825	2,825	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.74	2,443,500	12,398,100	-%
Mar 05, 2024	Fisher Asset Management, LLC	unchanged	-	161,144	843,057	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	94.35	5,312,660	9,099,790	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	24,095	128,254	-%
Feb 26, 2024	Virtu Financial LLC	new	-	72,000	72,000	0.01%

Are Funds Buying or Selling STRO?

Are funds buying STRO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STRO

No. of Funds

STRO Alerts

Point72 Asset Management, L.P. reported owning 7.7% of STRO [2024-04-05]

Unveiling Sutro Biopharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	point72 asset management, l.p.	7.7%	5,791,505	SC 13G
Feb 13, 2024	suvretta capital management, llc	9.5%	5,778,188	SC 13G/A
Feb 12, 2024	rubric capital management lp	5.49%	3,344,810	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	7.33%	4,467,796	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	5,823,922	SC 13G/A
Jan 17, 2024	integrated core strategies (us) llc	5.1%	3,106,844	SC 13G
Oct 10, 2023	adage capital partners gp, l.l.c.	5.86%	3,549,320	SC 13G
Feb 14, 2023	eventide asset management, llc	0%	0	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	3.1%	1,801,709	SC 13G/A
Feb 13, 2023	suvretta capital management, llc	9.7%	5,565,099	SC 13G/A

Recent SEC filings of Sutro Biopharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	4	Insider Trading
Apr 05, 2024	SC 13G	Major Ownership Report
Apr 02, 2024	424B5	Prospectus Filed
Apr 02, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 25, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Mar 22, 2024	4/A	Insider Trading
Mar 22, 2024	4/A	Insider Trading
Mar 22, 2024	4/A	Insider Trading

Peers (Alternatives to Sutro Biopharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Sutro Biopharma Inc News

Latest updates

Sutro Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	572.0%	113,721,000	16,924,000	10,412,000	12,674,000	8,632,000	25,147,000	28,096,000	5,897,000	10,654,000	8,517,000	28,049,000	14,660,000	8,278,000	17,823,000	9,469,000	7,152,000	11,305,000	12,277,000	10,525,000	8,629,000	19,086,000
Operating Expenses	15.8%	70,569,000	60,938,000	56,591,000	54,911,000	57,854,000	46,357,000	47,475,000	45,029,000	45,690,000	43,191,000	37,854,000	33,669,000	33,121,000	28,440,000	25,886,000	26,332,000	26,087,000	25,012,000	24,210,000	22,895,000	22,361,000
S&GA Expenses	10.1%	16,804,000	15,269,000	14,999,000	15,512,000	14,719,000	14,643,000	15,143,000	15,039,000	15,763,000	16,589,000	12,545,000	11,107,000	10,383,000	9,079,000	8,643,000	8,713,000	8,695,000	8,115,000	8,067,000	7,715,000	7,574,000
R&D Expenses	17.7%	53,765,000	45,669,000	41,592,000	39,399,000	43,135,000	31,714,000	32,332,000	29,990,000	29,927,000	26,602,000	25,309,000	22,562,000	22,738,000	19,361,000	17,243,000	17,619,000	17,392,000	16,897,000	16,143,000	15,180,000	14,787,000
EBITDA Margin	84.3%	-0.52	-3.33	-2.36	-1.60	-1.61	-1.62	-2.34	-2.02	-1.59	-0.42	-0.37	-0.51	-0.61	-	-	-	-	-	-	-	-
Interest Expenses	-37.8%	155,000	249,000	329,000	393,000	427,000	444,000	494,000	504,000	510,000	516,000	689,000	331,000	510,000	516,000	515,000	134,000	151,000	265,000	303,000	330,000	333,000
Income Taxes	758.1%	15,780,500	1,839,000	200,000	400,000	-	-	2,500,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	198.8%	46,872,000	-47,445,000	-38,373,000	-49,655,000	-34,594,000	-19,488,000	-23,512,000	-39,110,000	-38,125,000	-30,902,000	-6,152,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	83.5%	-0.58	-3.50	-2.50	-1.71	-1.72	-1.72	-2.48	-2.15	-1.71	-0.54	-0.47	-0.64	-0.75	-	-	-	-	-	-	-	-
Net Income	163.0%	31,065,000	-49,284,000	-38,524,000	-50,050,000	-34,594,000	-19,488,000	-26,012,000	-39,110,000	-38,125,000	-30,902,000	-6,152,000	-30,359,000	-59,544,000	17,139,000	29,872,000	-19,595,000	-14,789,000	-12,912,000	-13,793,000	-14,250,000	-1,493,000
Net Income Margin	80.4%	-0.69	-3.55	-2.51	-1.75	-1.76	-1.76	-2.52	-2.15	-1.71	-2.13	-1.15	-0.85	-0.75	-	-	-	-	-	-	-	-
Free Cashflow	142.0%	14,072,000	-33,502,000	-31,958,000	-61,754,000	-24,627,000	65,091,000	-3,949,000	-36,018,000	-22,343,000	-25,169,000	-6,026,000	-31,193,000	-19,642,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	9.0%	471	432	465	358	407	401	386	304	341	371	360	359	394	307	278	154	156	172	189	202	223
Current Assets	10.6%	422	381	412	304	353	347	332	229	219	251	278	266	378	292	258	127	129	136	162	177	210
Cash Equivalents	-15.4%	69.00	82.00	235	62.00	47.00	97.00	79.00	29.00	30.00	31.00	56.00	56.00	206	64.00	65.00	44.00	5.00	12.00	19.00	27.00	125
Net PPE	-1.8%	22.00	22.00	24.00	24.00	25.00	24.00	24.00	23.00	23.00	23.00	19.00	15.00	13.00	12.00	11.00	10.00	10.00	9.00	9.00	10.00	11.00
Liabilities	0.5%	321	319	310	173	190	171	177	83.00	89.00	88.00	52.00	51.00	62.00	63.00	71.00	72.00	59.00	62.00	69.00	72.00	92.00
Current Liabilities	27.4%	94.00	74.00	67.00	59.00	67.00	58.00	45.00	39.00	42.00	35.00	26.00	23.00	30.00	30.00	35.00	32.00	33.00	36.00	36.00	31.00	36.00
Long Term Debt	-	-	-	-	-	4.00	7.00	10.00	13.00	16.00	19.00	22.00	25.00	25.00	24.00	24.00	24.00	9.00	6.00	7.00	9.00	10.00
LT Debt, Non Current	-	-	-	-	-	4.00	7.00	10.00	13.00	16.00	19.00	22.00	25.00	25.00	24.00	24.00	24.00	9.00	6.00	7.00	9.00	10.00
Shareholder's Equity	33.2%	150	112	155	185	217	230	209	220	253	284	308	307	332	244	207	82.00	98.00	110	120	131	132
Retained Earnings	5.3%	-559	-590	-541	-502	-452	-418	-398	-372	-333	-295	-264	-258	-227	-168	-185	-215	-195	-180	-168	-154	-150
Additional Paid-In Capital	0.9%	709	703	696	688	670	649	609	594	586	579	572	566	560	412	392	297	293	291	287	285	282
Shares Outstanding	0.2%	61.00	61.00	60.00	60.00	57.00	49.00	47.00	46.00	46.00	46.00	46.00	46.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	278	-	-	-	251	-	-	-	850	-	-	-	261	-	-	-	236	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	142.0%	14,072	-33,502	-31,195	-60,991	-23,864	65,854	-3,186	-35,255	-21,580	-24,406	-5,263	-30,430	-18,879	-17,689	-12,500	-18,734	-13,156	-16,121	-15,601	-20,145	-5,935
Share Based Compensation	3.7%	6,223	6,003	6,661	6,021	5,852	6,782	6,696	6,974	6,887	6,495	5,907	3,952	3,087	3,112	3,011	2,707	2,683	2,880	2,463	2,286	2,070
Cashflow From Investing	79.4%	-23,513	-114,019	66,157	67,451	-37,882	-78,037	47,915	32,982	20,781	-2,242	5,876	-121,730	15,807	296	-57,136	41,637	7,942	9,812	9,194	-78,079	2,025
Cashflow From Financing	45.6%	-3,125	-5,740	137,661	8,758	12,221	29,847	5,485	760	506	963	-39.00	1,826	144,854	17,272	91,419	15,702	-1,780	-1,127	-819	-458	87,855

STRO Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 153,731	$ 67,772	$ 61,880
Operating expenses
Research and development	180,425	137,171	104,400
General and administrative	62,584	59,544	56,004
Total operating expenses	243,009	196,715	160,404
Loss from operations	(89,278)	(128,943)	(98,524)
Interest income	14,510	3,455	577
Unrealized gain (loss) on equity securities	9,917	12,130	(4,454)
Non-cash interest expense related to the sale of future royalties	(12,570)
Interest and other income (expense), net	(11,180)	(3,346)	(3,137)
Loss before provision for income taxes	(88,601)	(116,704)	(105,538)
Provision for income taxes	18,192	2,500
Net loss	$ (106,793)	$ (119,204)	$ (105,538)
Net loss per share, basic	$ (1.78)	$ (2.35)	$ (2.29)
Net loss per share, diluted	$ (1.78)	$ (2.35)	$ (2.29)
Weighted-average shares used in computing basic loss per share	60,163,542	50,739,185	46,119,089
Weighted-average shares used in computing diluted loss per share	60,163,542	50,739,185	46,119,089

STRO Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 69,268	$ 47,254
Marketable securities	264,413	255,090
Investment in equity securities	41,937	32,020
Accounts receivable	36,078	7,122
Prepaid expenses and other current assets	9,846	11,667
Total current assets	421,542	353,153
Property and equipment, net	21,940	24,621
Operating lease right-of-use assets	22,815	26,443
Other non-current assets	3,567	1,855
Restricted cash	872	872
Total assets	470,736	406,944
Current liabilities:
Accounts payable	9,440	4,797
Accrued compensation	14,686	13,142
Deferred revenue-current	20,666	16,759
Operating lease liability - current	6,420	4,585
Debt-current	4,061	12,500
Accrued expenses and other current liabilities	38,473	14,764
Total current liabilities	93,746	66,547
Deferred revenue, non-current	53,379	89,885
Operating lease liability - non-current	23,154	29,574
Debt-non-current	0	3,771
Deferred royalty obligation related to the sale of future royalties	149,114
Other non-current liabilities	1,694	119
Total liabilities	321,087	189,896
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2023 and 2022; 0 shares issued and outstanding as of December 31, 2023 and 2022
Common stock, $0.001 par value - 300,000,000 shares authorized as of December 31, 2023 and 2022; 61,009,829 and 57,499,541 shares issued and outstanding as of December 31, 2023 and 2022, respectively	61	58
Additional paid-in-capital	708,975	670,223
Accumulated other comprehensive income (loss)	21	(618)
Accumulated deficit	(559,408)	(452,615)
Total stockholders’ equity	149,649	217,048
Total Liabilities and Stockholders’ Equity	$ 470,736	$ 406,944

About Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

CEO	Mr. William J. Newell J.D.
WEBSITE	sutrobio.com
INDUSTRY	Biotechnology
EMPLOYEES	297

Sutro Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Sutro Biopharma Inc? What does STRO stand for in stocks?

STRO is the stock ticker symbol of Sutro Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sutro Biopharma Inc (STRO)?

As of Tue Apr 23 2024, market cap of Sutro Biopharma Inc is 232.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STRO stock?

You can check STRO's fair value in chart for subscribers.

What is the fair value of STRO stock?

You can check STRO's fair value in chart for subscribers. The fair value of Sutro Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sutro Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sutro Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether STRO is over valued or under valued. Whether Sutro Biopharma Inc is cheap or expensive depends on the assumptions which impact Sutro Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STRO.

What is Sutro Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, STRO's PE ratio (Price to Earnings) is -2.18 and Price to Sales (PS) ratio is 1.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STRO PE ratio will change depending on the future growth rate expectations of investors.